ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,304.72
0.70%
Dow Jones
39,069.59
0.01%
US Dollar vs MXN
16.6998
0.00%
Brent Oil
81.965
0.00%
Bitcoin
69,143.00
0.89%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Voyager Therapeutics Inc (VYGR)

  7. Voyager Therapeutics Inc (VYGR) Noticias

VYGR

Voyager Therapeutics (VYGR)

Voyager Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:VYGR
FechaHoraFuenteTítuloSímboloCompañía
16/05/202406:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VYGRVoyager Therapeutics Inc
16/05/202406:00GlobeNewswire Inc.Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s DiseaseNASDAQ:VYGRVoyager Therapeutics Inc
13/05/202415:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VYGRVoyager Therapeutics Inc
13/05/202415:01GlobeNewswire Inc.Voyager Therapeutics Reports First Quarter 2024 Financial and Operating ResultsNASDAQ:VYGRVoyager Therapeutics Inc
08/05/202405:00GlobeNewswire Inc.Voyager Therapeutics Presents Data for Second-Generation, TRACER™-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual MeetingNASDAQ:VYGRVoyager Therapeutics Inc
06/05/202406:00GlobeNewswire Inc.Voyager Therapeutics Announces First Quarter 2024 Conference Call and WebcastNASDAQ:VYGRVoyager Therapeutics Inc
22/04/202415:30GlobeNewswire Inc.Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual MeetingNASDAQ:VYGRVoyager Therapeutics Inc
16/04/202406:00GlobeNewswire Inc.Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone PaymentNASDAQ:VYGRVoyager Therapeutics Inc
26/03/202415:01GlobeNewswire Inc.Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:VYGRVoyager Therapeutics Inc
13/03/202406:00GlobeNewswire Inc.Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical OfficerNASDAQ:VYGRVoyager Therapeutics Inc
28/02/202415:01GlobeNewswire Inc.Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating ResultsNASDAQ:VYGRVoyager Therapeutics Inc
26/02/202406:00GlobeNewswire Inc.Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich’s Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone PaymentNASDAQ:VYGRVoyager Therapeutics Inc
22/02/202415:36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VYGRVoyager Therapeutics Inc
21/02/202414:16Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VYGRVoyager Therapeutics Inc
21/02/202406:00GlobeNewswire Inc.Voyager Therapeutics Announces Fourth Quarter 2023 Conference Call and WebcastNASDAQ:VYGRVoyager Therapeutics Inc
20/02/202406:00GlobeNewswire Inc.Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer’s Disease and Advances Program into Late ResearchNASDAQ:VYGRVoyager Therapeutics Inc
07/02/202406:00GlobeNewswire Inc.Voyager Therapeutics to Present at the Oppenheimer Annual Life Sciences ConferenceNASDAQ:VYGRVoyager Therapeutics Inc
17/01/202415:20Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:VYGRVoyager Therapeutics Inc
08/01/202415:04Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:VYGRVoyager Therapeutics Inc
04/01/202421:45GlobeNewswire Inc.Voyager Therapeutics Announces Pricing of Public OfferingNASDAQ:VYGRVoyager Therapeutics Inc
04/01/202415:14GlobeNewswire Inc.Voyager Therapeutics Announces Proposed Public OfferingNASDAQ:VYGRVoyager Therapeutics Inc
03/01/202406:00GlobeNewswire Inc.Voyager Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:VYGRVoyager Therapeutics Inc
02/01/202406:46Dow Jones NewsVoyager Therapeutics Shares Leap Premarket on Novartis CollaborationNASDAQ:VYGRVoyager Therapeutics Inc
02/01/202406:00GlobeNewswire Inc.Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene TherapiesNASDAQ:VYGRVoyager Therapeutics Inc
06/12/202306:00GlobeNewswire Inc.Voyager Therapeutics Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy ProgramNASDAQ:VYGRVoyager Therapeutics Inc
06/11/202315:01GlobeNewswire Inc.Voyager Therapeutics Reports Third Quarter 2023 Financial and Operating ResultsNASDAQ:VYGRVoyager Therapeutics Inc
30/10/202306:00GlobeNewswire Inc.Voyager Therapeutics Announces Third Quarter 2023 Conference Call and WebcastNASDAQ:VYGRVoyager Therapeutics Inc
25/09/202306:00GlobeNewswire Inc.Voyager Therapeutics to Present at the Chardan Genetic Medicines ConferenceNASDAQ:VYGRVoyager Therapeutics Inc
30/08/202306:00GlobeNewswire Inc.Voyager Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:VYGRVoyager Therapeutics Inc
07/08/202307:00GlobeNewswire Inc.Voyager Therapeutics Announces Appointment of Beth Shafer as Chief Business OfficerNASDAQ:VYGRVoyager Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:VYGR

Su Consulta Reciente

LSE
AK16
Citi Fun 31
NASDAQ
ABAOMXX
Hsbc Usa Inc Itm Digital...
GATE
DFAUSDT
DeFine Art
LSE
90KL
Nat.grid1.6574%
NYSE
ESE
ESCO Technologies
BIT
UI667C
Unicredit Bank
LSE
FC58
Nat.grid 43
COIN
SWISSETH
Swiss Token
NASDAQ
QYLD
Global X Funds Global X ...
TSX
4495
i Cubed Systems
NASDAQ
CURI
CuriosityStream
TSXV
ECR
Cartier Resources
BIT
1MCD
Mcdonalds
NASDAQ
TLF
Tandy Leather Factory
LQID
STACBTC
NASDAQ
SCRMW
Screaming Eagle Acquisit...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados